Literature DB >> 33553512

Alendronate and omeprazole in combination reduce angiogenic and growth signals from osteoblasts.

Tormod B Krüger1, Bente B Herlofson1, Aina M Lian2, Unni Syversen2,3,4, Janne E Reseland2.   

Abstract

OBJECTIVE: Due to gastrointestinal side effects of oral bisphosphonates (BPs), proton pump inhibitors (PPIs) are often prescribed. PPIs may enhance the risk of osteonecrosis of the jaw, a rare side effect of BPs. Therefore, the objective of this study was to evaluate the effects of the oral BP alendronate (ALN) and the PPI omeprazole (OME) alone and in combination on primary human osteoblasts and gingival fibroblasts in vitro.
METHODS: Human gingival fibroblasts and normal human osteoblasts were incubated with either 5 μM of ALN or 1 μM of OME, or ALN + OME for 1, 3, 7 or 14 days. Effect on viability was evaluated by the lactate dehydrogenase activity in the medium and on proliferation by quantifying 3H-thymidin incorporation. Multianalyte profiling of proteins in cell culture media was performed using the Luminex 200TM system to assess the effect on selected bone markers and cytokines.
RESULTS: The proliferation of osteoblasts and fibroblasts was reduced upon exposure to ALN + OME. ALN induced an early, temporary rise in markers of inflammation, and OME and ALN + OME promoted a transient decline. An initial increase in IL-13 occurred after exposure to all three options, whereas ALN + OME promoted IL-8 release after 7 days. OME and ALN + OME promoted a transient reduction in vascular endothelial growth factor (VEGF) from osteoblasts, whereas ALN and ALN + OME induced a late rise in VEGF from fibroblasts. Osteoprotegerin release was enhanced by ALN and suppressed by OME and ALN + OME.
CONCLUSIONS: ALN + OME seemed to exaggerate the negative effects of each drug alone on human osteoblasts and gingival fibroblasts. The anti-proliferative effects, modulation of inflammation and impairment of angiogenesis, may induce unfavorable conditions in periodontal tissue facilitating development of osteonecrosis.
© 2021 The Author(s).

Entities:  

Keywords:  Alendronate; Bisphosphonates; Bone repair; Omeprazole; Osteonecrosis; Proton pump inhibitors

Year:  2021        PMID: 33553512      PMCID: PMC7856318          DOI: 10.1016/j.bonr.2021.100750

Source DB:  PubMed          Journal:  Bone Rep        ISSN: 2352-1872


  62 in total

1.  Interleukin-6 promotes destabilized angiogenesis by modulating angiopoietin expression in rheumatoid arthritis.

Authors:  Ken Kayakabe; Takashi Kuroiwa; Noriyuki Sakurai; Hidekazu Ikeuchi; Anastasie Tshilela Kadiombo; Toru Sakairi; Takayuki Matsumoto; Akito Maeshima; Keiju Hiromura; Yoshihisa Nojima
Journal:  Rheumatology (Oxford)       Date:  2012-05-16       Impact factor: 7.580

2.  Proton pump inhibitor use and the antifracture efficacy of alendronate.

Authors:  Bo Abrahamsen; Pia Eiken; Richard Eastell
Journal:  Arch Intern Med       Date:  2011-02-14

Review 3.  Underlying Mechanisms and Therapeutic Strategies for Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ).

Authors:  Yasuo Endo; Hiroyuki Kumamoto; Masanori Nakamura; Shunji Sugawara; Teruko Takano-Yamamoto; Keiichi Sasaki; Tetsu Takahashi
Journal:  Biol Pharm Bull       Date:  2017       Impact factor: 2.233

4.  The impact of bisphosphonates on the osteoblast proliferation and Collagen gene expression in vitro.

Authors:  Felix Peter Koch; Sareh Said Yekta; Christina Merkel; Thomas Ziebart; Ralf Smeets
Journal:  Head Face Med       Date:  2010-07-09       Impact factor: 2.151

5.  Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.

Authors:  Robert E Marx
Journal:  J Oral Maxillofac Surg       Date:  2003-09       Impact factor: 1.895

6.  Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung.

Authors:  Chun Geun Lee; Holger Link; Peter Baluk; Robert J Homer; Svetlana Chapoval; Vineet Bhandari; Min Jong Kang; Lauren Cohn; Yoon Keun Kim; Donald M McDonald; Jack A Elias
Journal:  Nat Med       Date:  2004-09-19       Impact factor: 53.440

Review 7.  Pathophysiology of Osteonecrosis of the Jaws.

Authors:  Tara Aghaloo; Renna Hazboun; Sotirios Tetradis
Journal:  Oral Maxillofac Surg Clin North Am       Date:  2015-09-26       Impact factor: 2.802

8.  Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users.

Authors:  P A Eiken; D Prieto-Alhambra; R Eastell; B Abrahamsen
Journal:  Osteoporos Int       Date:  2017-06-29       Impact factor: 4.507

9.  The enigma of atypical femoral fractures: A summary of current knowledge.

Authors:  Morten Schultz Larsen; Hagen Schmal
Journal:  EFORT Open Rev       Date:  2018-09-12

10.  Tocilizumab, a Potent Interleukin-6 Receptor Inhibitor, Decreases Bone Resorption and Increases the Rate of Bacterial Infection After Tooth Extraction in Rats.

Authors:  Maria Imaculada de Queiroz Rodrigues; Joyce Ohana de Lima Martins; Paulo Goberlânio de Barros Silva; Antônio Ernando Carlos Ferreira Júnior; Maria Elisa Quezado Lima Verde; Fabrício Bitú Sousa; Mário Rogério Lima Mota; Ana Paula Negreiros Nunes Alves
Journal:  J Oral Maxillofac Surg       Date:  2020-08-15       Impact factor: 1.895

View more
  2 in total

1.  Effects of Vitamin C Combined with Growth Inhibitors on Gastrointestinal Bleeding in Cirrhosis.

Authors:  Shimei Wang; Yuanyuan Peng
Journal:  Contrast Media Mol Imaging       Date:  2022-07-18       Impact factor: 3.009

2.  Do patients with gastroesophageal reflux disease exhibit compromised bone quality prior to proton pump inhibitor therapy?

Authors:  Kristin M Aasarød; Mats P Mosti; Malin T Finstad; Astrid K Stunes; Reidar Fossmark; Unni Syversen
Journal:  Bone Rep       Date:  2021-05-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.